THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES;THE UNIVERSITY OF NORTH CAROLINA AT CHAP; AS REPRESENTED BY THE SECRETARY;MUSC FOUNDATION FOR RESEARCH DEVELOPMENT;DUKE UNIVERSITY;THE UNITED STATES OF AMERICA; DEPARTMENT OF HEALTH AND HUMAN SERVICES
Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer.
